Physician profile
Carlo E Adams
NPI 1124225255
$3,442.33
in general payments reported to CMS, 2019-2025
33 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $469 · 2021: $577 · 2022: $266 · 2023: $365 · 2024: $409 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $723.88 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $470.77 | 2019-2024 | Ztlido |
| Abbvie INC. | $402.73 | 2021-2025 | Botox, Ubrelvy |
| Collegium Pharmaceutical, INC. | $219.92 | 2019-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $189.08 | 2023-2025 | Qutenza |
| Nevro Corp. | $134.72 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $107.61 | 2022-2024 | Euflexxa |
| Electronic Waveform Lab, INC. | $103.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.67 | 2019 | |
| Mdd US Operations, LLC | $86.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.27 | 2019-2020 | |
| Merz North America, INC. | $73.15 | 2019-2020 | |
| Abbott Laboratories | $72.65 | 2019 | |
| Azurity Pharmaceuticals, INC. | $70.49 | 2023-2024 | Horizant, Adthyza, Horizant |
| Vertiflex, INC. | $69.88 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $65.26 | 2019 | |
| Sentynl Therapeutics, INC. | $63.78 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $59.05 | 2020-2021 | |
| Pfizer INC. | $48.99 | 2019 | |
| Amgen INC. | $48.51 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $36.62 | 2024 | Gvoke Hypopen |
| Assertio Therapeutics, INC. | $31.59 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.79 | 2020-2021 | |
| Grt US Holding, INC. | $26.80 | 2021 | |
| Biodelivery Sciences International, INC. | $20.77 | 2020 | |
| Spr Therapeutics, INC | $19.17 | 2024 | Sprint Pns System |
| Pacira Therapeutics, INC. | $16.24 | 2019 | |
| Zyla Life Sciences, INC. | $15.17 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.90 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $12.64 | 2019 | |
| Kaleo, INC. | $11.41 | 2019 | |
| Amarin Pharma, INC. | $11.23 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlo Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.